NEW YORK (GenomeWeb News) – The European Union plans to fund new research seeking to establish the clinical utility of epigenetic biomarkers for blood-based diseases under its Blueprint consortium program, a €30 million ($39.8 million) effort focused on advancing hematopoietic biomarkers.

The Blueprint program is supporting several projects to speed the development, validation, and use of epigenetic biomarkers in treating diseases such as myeloid and lymphoblastic leukemias, myelodysplastic syndromes, lymphomas, and type 1 diabetes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.